Pharmaceutical composition for nasal delivery

US10653690B1 · kind B1 · utility

Assignee

• OREXO AB · SE

Inventors

• Jonas Sävmarker · Uppsala, SE
• Robert Rönn · Uppsala, SE
• Andreas Fischer · Castro Valley, US

Key dates

• Filing date: Jul 9, 2019
• Grant date: May 19, 2020
• Expiry date: Jul 9, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/36
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist. The pharmaceutical composition includes a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The pharmaceutical composition is preferably in the form of a powder produced by spray-drying, which is subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. The pharmaceutical composition may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.